| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Stachyose tetrahydrate does not target a specific receptor but functions as a prebiotic. It is not digested in the upper gastrointestinal tract and reaches the colon intact, where it is fermented by beneficial gut bacteria such as Bifidobacteria and Lactobacilli. This fermentation produces short-chain fatty acids that support gut health, enhance immune function, and may prevent colon cancer cell growth by promoting probiotic proliferation.
|
|---|---|
| ln Vitro |
Stachyose tetrawater causes apoptosis and inhibits Caco-2 cell division in a dose-dependent way [1]. By encouraging lactic acid bacteria (LAB) to create more α-galactosidase to hydrolyze stachyose, stachyose greatly enhances LAB growth [2].
In vitro, stachyose tetrahydrate acts as a prebiotic, promoting the proliferation of beneficial gut bacteria. It can indirectly prevent colon cancer cell growth by producing beneficial materials in the intestine. The compound's effects on gut microbiota have been characterized in various in vitro fermentation models using human fecal inocula. |
| ln Vivo |
In vivo, stachyose tetrahydrate has been shown to promote the growth of beneficial gut bacteria and improve digestive health. It can indirectly prevent colon cancer cell growth by promoting the proliferation of probiotics or producing beneficial materials in the intestine. The compound is used as a prebiotic in functional foods and dietary supplements.
|
| Enzyme Assay |
For in vitro fermentation assays, stachyose tetrahydrate is incubated with human fecal inocula or pure cultures of gut bacteria (e.g., Bifidobacterium, Lactobacillus). The compound is added to anaerobic culture media at concentrations of 0.5-5% (w/v). Bacterial growth is monitored by measuring optical density or by qPCR. Short-chain fatty acid production is measured by gas chromatography.
|
| Cell Assay |
For in vitro cell-based assays, stachyose tetrahydrate is tested on colon cancer cell lines to evaluate its indirect anti-cancer effects. Colon cancer cells are cultured in media containing fermentation supernatants from stachyose-treated bacterial cultures. Cell viability and proliferation are assessed using MTT assays. Apoptosis is evaluated by flow cytometry. The compound itself is not directly cytotoxic to cancer cells.
|
| Animal Protocol |
For in vivo animal experiments, stachyose tetrahydrate is typically administered orally to rodents. The compound is given at doses ranging from 100-1000 mg/kg daily for 2-8 weeks. Fecal samples are collected for microbiome analysis by 16S rRNA sequencing. Short-chain fatty acid levels are measured in cecal contents. Intestinal barrier function is assessed by measuring tight junction protein expression and permeability. Immune parameters are evaluated in serum and intestinal tissues.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for stachyose tetrahydrate indicate that it is not absorbed in the upper gastrointestinal tract. The compound reaches the colon intact, where it is fermented by gut microbiota. Its molecular weight is 738.64 g/mol and formula is C₂₄H₅₀O₂₅. The compound has a melting point of 95-105°C and a density of 1.84 g/cm³. It is soluble in water.
|
| Toxicity/Toxicokinetics |
Toxicological data for stachyose tetrahydrate indicate that it is generally well-tolerated. As a naturally occurring oligosaccharide, it is considered safe for consumption. High doses may cause gastrointestinal symptoms such as bloating and flatulence due to fermentation. The compound is classified as a research-grade reagent and is not for human therapeutic use, although it is used in dietary supplements.
|
| References | |
| Additional Infomation |
Stachyose tetrahydrate is an oligosaccharide.
Stachyose tetrahydrate is a research-use only compound and has not been approved as a therapeutic drug. It is also known as D-stachyose tetrahydrate. Its molecular weight is 738.64, and its formula is C₂₄H₅₀O₂₅. The compound is used as a prebiotic in functional foods and dietary supplements. It is available from various research chemical suppliers for gut microbiota and prebiotic research. |
| Molecular Formula |
C24H42O21.4(H2O)
|
|---|---|
| Molecular Weight |
738.65
|
| Exact Mass |
738.264
|
| CAS # |
10094-58-3
|
| Related CAS # |
Stachyose hydrate;54261-98-2;Stachyose;470-55-3
|
| PubChem CID |
2724335
|
| Appearance |
White to yellow solid powder
|
| Boiling Point |
1044.2ºC at 760 mmHg
|
| Melting Point |
95-105 °C
|
| Flash Point |
585.3ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| Index of Refraction |
133 ° (C=5, H2O)
|
| LogP |
-8
|
| Hydrogen Bond Donor Count |
18
|
| Hydrogen Bond Acceptor Count |
25
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
49
|
| Complexity |
933
|
| Defined Atom Stereocenter Count |
19
|
| SMILES |
C([C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)OC[C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)OC[C@@H]3[C@H]([C@@H]([C@H]([C@H](O3)O[C@]4([C@H]([C@@H]([C@H](O4)CO)O)O)CO)O)O)O)O)O)O)O)O)O)O
|
| InChi Key |
UQZIYBXSHAGNOE-XNSRJBNMSA-N
|
| InChi Code |
InChI=1S/C24H42O21/c25-1-6-10(28)14(32)17(35)21(41-6)39-3-8-11(29)15(33)18(36)22(42-8)40-4-9-12(30)16(34)19(37)23(43-9)45-24(5-27)20(38)13(31)7(2-26)44-24/h6-23,25-38H,1-5H2/t6-,7-,8-,9-,10+,11+,12-,13-,14+,15+,16+,17-,18-,19-,20+,21+,22+,23-,24+/m1/s1
|
| Chemical Name |
(2S,3R,4S,5R,6R)-2-[[(2R,3R,4S,5R,6S)-6-[[(2R,3S,4S,5R,6R)-6-[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methoxy]-3,4,5-trihydroxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~338.46 mM)
H2O : ~100 mg/mL (~135.38 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (2.82 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (2.82 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (2.82 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (135.38 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3538 mL | 6.7691 mL | 13.5382 mL | |
| 5 mM | 0.2708 mL | 1.3538 mL | 2.7076 mL | |
| 10 mM | 0.1354 mL | 0.6769 mL | 1.3538 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
